Shaanxi Micot Pharmaceutical said its injectable neuroprotective agent MT-200605 met Phase 2 endpoints in acute ischemic stroke. The program centers on a small-molecule TrkB agonist designed to cross the blood-brain barrier and activate BDNF/TrkB signaling while targeting reactive oxygen species implicated in the post-stroke ischemic cascade. The report frames MT-200605 as an approach to interrupt disease biology after vascular injury, with development focused on supporting neurological repair rather than solely managing symptoms. For biotech investors watching CNS translation risk, the result adds momentum to a mechanism that combines neurotrophic signaling activation with oxidative stress mitigation, both key drivers of secondary injury after ischemic stroke. The next phase will determine whether endpoint success holds at larger scale and whether safety signals emerge given the challenge of dosing CNS-penetrant small molecules in acute settings.